Arcellx Q1 2024 Earnings Report

Arcellx EPS Results

• Actual EPS: -$0.14
• Consensus EPS: -$0.51
• Beat/Miss: Beat by +$0.37
• One Year Ago EPS: -$0.58

Arcellx Revenue Results

• Actual Revenue: $39.26 million
• Expected Revenue: $20.67 million
• Beat/Miss: Beat by +$18.59 million
• YoY Revenue Growth: +119.20%

Arcellx Announcement Details

• Quarter: Q1 2024
• Date: 5/9/2024
• Time: After Market Closes

Arcellx (NASDAQ:ACLX), together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.